NCT05036434 2026-01-23ACCOMPLISHNational Cancer Center, KoreaPhase 2 Active not recruiting30 enrolled
NCT04519151 2023-06-08Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian CancerSheba Medical CenterPhase 2 Recruiting24 enrolled